BioAffinity Technologies (BIAF) announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. The company stated this patent strengthens the international protection of its diagnostic platform that powers its flagship test, CyPath Lung. The Canadian patent, titled “System and Method for Determining Lung Health,” protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- bioAffinity Technologies Secures Chinese Patent for Lung Cancer Detection
- BioAffinity receives China patent for noninvasive lung cancer diagnostic
- BioAffinity Technologies gets China patent for siRNA-based cancer therapy
- bioAffinity Receives Nasdaq Non-Compliance Notice
- BioAffinity gets U.S. patent for novel broad spectrum cancer therapies